A new consumer healthcare company
GSK’s Consumer Healthcare business is on track to become an independent company through a proposed demerger from GSK in mid-2022. The new business, to be named Haleon, is expected to be a world-leader in consumer healthcare, offering the prospect of attractive organic sales growth, operating margin expansion and consistent high cash generation.
Led by its purpose to deliver better everyday health with humanity, it will be strongly positioned to play a vital role in a growing sector that is more relevant than ever. Haleon will have a world-class portfolio of category-leading global brands, including Sensodyne, Voltaren, Panadol and Centrum, brands that are trusted by healthcare professionals, customers and people worldwide to improve the health and wellbeing of individuals and their communities.
Demerger
Shareholders can view the Prospectus in relation to the proposed admission of the Haleon plc ordinary shares along with associated documents via the links below. Further information on the demerger, along with details of the General Meeting to be held on Wednesday 6 July 2022 at 2.30pm, can be found here.
- Prospectus
- Articles of Association of Haleon plc
- Deloitte’s written consent letter
- Deloitte’s report on the Unaudited Pro Forma Financial Information of the Group
- Deloitte’s report on the Historical Financial Information of GlaxoSmithKline Consumer Healthcare Holdings (No.2) Limited
- Deloitte’s report on the Pfizer Historical Financial Information
GSK announces further appointments to Designate Haleon Board
On 30 May 2022 we announced the appointments of Asmita Dubey, Marie-Anne Aymerich and Bryan Supran to the Designate Haleon Board, the new independent company to be formed following the demerger of the GSK Consumer Healthcare business, expected in July 2022.
These appointments follow the appointment of Sir Dave Lewis as Non-Executive Chair Designate in December 2021 and the appointment of six directors in March 2022 and complete the formation of the Designate Haleon Board. This Board will benefit from an appropriate mix of skills, experience, and diversity to support Haleon as a listed company. Read the press release here.
Consumer Healthcare Capital Markets Day
GSK's Consumer Healthcare Capital Markets Day took place on Monday 28 February 2022. This event provided details on our strategy, brands, capabilities and operations, as well as detailed financial information and future growth ambitions ahead of the proposed listing on the London Stock Exchange following the anticipated demerger from GSK mid-2022.
Designate Chair
GSK announces Sir Dave Lewis appointed Non-Executive Chair Designate of independent Consumer Healthcare company
Press releases
Redburn CEO conference 2021- Brian McNamara (01 December 2021)
Brian McNamara, CEO of GSK Consumer Healthcare participated virtually in the 2021 Redburn CEO Conference. He provided an overview of our business and broader industry.
Exane BNP Paribas 23rd European CEO Conference – Brian McNamara (10 June 2021)
Brian McNamara, CEO, GSK Consumer Healthcare, presented at the conference and provided an introduction to GSK Consumer Healthcare and outlined our purpose, strategy, category-leading brands and capabilities, as well as an overview of the consumer healthcare sector.
Click here to download slides
Investor contacts
Sonya Ghobrial
Head of IR Consumer Healthcare GSK
Email: sonya.x.ghobrial@gsk.com
Media contacts
Global Headquarters (London, UK)
Tim Foley
VP, Global Corporate Media Relations
Madeleine Breckon
Director, Global Corporate Media Relations, Pharmaceuticals
Simon Moore
Director, Global Corporate Media Relations, Vaccines and Global Public Health
Tel: +44 (0)20 8047 5502
Email: corporate.media@gsk.com
USA (Philadelphia)
Kristen Neese
VP, Global Product & Pipeline Communications & US Corporate Communications
Email: kristen.x.neese@gsk.com
Kathleen Quinn
Head, US Corporate Communications
Email: kathleen.x.quinn@gsk.com
You may be interested in
Haleon will continue to use and protect your personal information in accordance with the same notices and practices in effect prior to our divestiture from GSK. The GSK Privacy Notice explains how we collect, use, share and protect your personal information, as well as how you can exercise your rights in regard to your personal information. Upon divestiture, Haleon will update the Privacy Notice to identify the new company (“Haleon”) and to let you know how to reach the new company with questions or requests related to your personal information.